All In Biotech

Drug Trial Radar · NCT05785741

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 in Subjects With Advanced/Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Aug 17, 2023

Primary completion

Dec 30, 2027

Study completion Apr 30, 2028

Sponsor

Lead sponsor
DualityBio Inc.Industry
Sponsor type
Industry
First posted
Mar 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • DB-1310Drug

    Administered I.V.

  • TrastuzumabDrug

    Administered I.V.

  • OsimertinibDrug

    Oral

  • capecitabineDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by CTCAE v5.0. Percentage of participants in Part 1 with DLTsTime frame: up to 21 days after Cycle 1 Day 1
  2. Phase 1: Percentage of Participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE v5.0.Time frame: Up to follow-up period, approximately 1 year post-treatment
  3. Phase 1: Percentage of Participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.Time frame: Up to follow-up period, approximately 1 year post-treatment
  4. Maximum Tolerated Dose (MTD) of DB-1310Time frame: 12 months
  5. Phase 1: Recommended Phase 2 Dose (RP2D) of DB-1310Time frame: 12 months
  6. Phase 2a: Percentage of Participants with Treatment Emergent adverse events (TEAEs) as assessed by CTCAE v5.0.Time frame: Up to follow-up period, approximately 1 year post-treatment
  7. Phase 2a: Percentage participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.Time frame: Up to follow-up period, approximately 1 year post-treatment
  8. Phase 2a: Percentage of Objective Response Rate (ORR) as assessed by RECIST 1.1.Time frame: Up to follow-up period, approximately 1 year post-treatment

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California, Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • UCLA Hematology/Oncology - Santa Monica

    Santa Monica, California · Recruiting

  • Research Site 117

    Coral Gables, Florida · Withdrawn

  • D&H Cancer Research Center LLC

    Margate, Florida · Withdrawn

  • Sarah Cannon Research Institute at Florida Cancer Specialists

    Orlando, Florida · Recruiting

  • BRCR global

    Plantation, Florida · Recruiting

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • BRCR Medical Center Inc.

    Tamarac, Florida · Recruiting

  • Research Site 111

    Atlanta, Georgia · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Henry Ford Health System

    Detroit, Michigan · Recruiting

  • Research site 119

    Florham Park, New Jersey · Active not recruiting

  • Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center

    Cincinnati, Ohio · Recruiting

  • Tennessee Oncology, PLLC

    Nashville, Tennessee · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Hunan cancer hospital

    Changsha, Hunan, China · Recruiting

  • Jiangsu Province hospital

    Nanjing, Jiangsu, China · Recruiting

  • Affiliated Hospital of Jiangnan University

    Wuxi, Jiangsu, China · Recruiting

  • The first hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China · Recruiting

  • Research Site 222

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.